1 / 12

talian

www.italiansarcomagroup.org. I. I. talian. talian. Started June 1997. S. S. arcoma. arcoma. G. G. roup. roup. Formalized October 2002. 6. 8. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 5. 3. 3. 2. 1.

evette
Download Presentation

talian

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. www.italiansarcomagroup.org I I talian talian Started June 1997 S S arcoma arcoma G G roup roup Formalized October 2002

  2. 6 8 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 5 3 3 2 1 Italian Sarcoma Group 1 BELGIUM 68 Centers • 14 National Institutes • 14 Universities • 34 Pubblic Hospitals • 6 Private Hospitals 1 1 10 210 members at november 2005

  3. Italian Sarcoma Group Osteosarcoma Protocols •ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts JCO 2005 • ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 ptsASCO 2005 • ISG/OS I (localized disease) activated 4/2001, 212 pts • EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 79 pts • High risk (relapsed patients) activated 12/2002, 28 pts

  4. Italian Sarcoma Group Ewing’s Sarcoma Protocols • ISG/SSG III (standard risk) activated 6/99, 240 pts • ISG/SSG IV (high risk) activated 6/99, 74 pts ASCO 2005 • ISG/AIEOP (very high risk) activated 12/2002, 19 pts • Relapsed Patients activated 12/2002, 22 pts

  5. Italian Sarcoma Group Adult soft tissue sarcomas - Protocols • ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk localized disease) with Spanish Group (222 pts) • ISG/STS 03/02 (neodjuvant IFO+RT in retroperitoneal) (15 pts) • HD-IFX in continuous infusion (2nd-4th line) • Gemcytabine in leiomyosarcomas (2nd-3rd line) • Paclitaxel in angiosarcomas (2a line) • MiniallogenicTransplant(advanced disease, responsive patients) • Imatinib in advanced chordoma (35 pts)

  6. GIST Protocols • • GIOTTO (observational, 2004-2005, in collaboration with Novartis) (>700 pts) • • REGISTER (retrospective, histhological) • • 62024 (adjuvant Imatinib), intergroup with EORTC • • Institutions from the ISG participated in the following studies on new agents in GIST: • SU11248 (international) CLOSED • •PTK787 (international) • •AMG706 (international)

  7. Italian Sarcoma Group Possible accrual Italian Population : 57 Millions Osteosarcoma: 90/120 (75%!) Ewing’s Sarcoma: 50/60 (80%!) Adult soft tissue sarcomas: 700/1400 (50%?)

  8. Started January 1st, 2005 - 3 year project Total grant: 2.530.500,00 Euro Website: WWW.PROTHETS.ORG

  9. Dr. Piero Picci (Co-ordinator) *Partner 1Istituti Ortopedici Rizzoli (IOR, Italy) Dr.ssa Katia Scotlandi *Partner 2 Institut National de la Santé et de la Recherche Médicale (INSERM, France) Pr. Alain Bernard *Partner 3 Laboratory for Experimental Orthopaedic Research (UKM, Germany) Dr. Frans van Valen *Partner 4 University of Helsinki (UH.DMG, Finland) Prof. Sakari Knuutila *Partner 5 Department of Pathology, University of Valencia (UVEG, Spain) Prof. Antonio Lombart-Bosch *Partner 6 Children´s Cancer Research Institute (CCRI, Austria) Prof. Dr. Heinrich Kovar *Partner 7 Université Paris 7 Denis-Diderot (UP7 DD, France) Dr. Bernard Perbal *Partner 8 Centre National de la Recherche Scientifique (CNRS, France) Dr. Claude Malvy *Partner 9 Belozersky Inst. of Physico-Chemical Biology of the Moscow State Univ. (BI.MSU) Dr.ssa Marina Gottikh *Partner 10 GenX Laboratories srl (GENX, Italy) Dr. Alessandro Borsatti *Partner 11MABGENE S.A. (MABG, France) Agnès Leconte

  10. PROTHETS - OBJECTIVES • Prognostic factors: fusion transcripts, secondary cytogenetic and molecular alterations, CD99, IGF-IR, NOVH, erbB-2, TTF1 • Targeted therapeutic approaches: EWS/FLI1, CD99, erbB-2, IGF-IR, TRAIL • Genomic profiles for evaluation of tumor progression and response to chemotherapy

  11. 87 primary or established cell lines 445 paraffin block material 145 frozen material 80 serum collected from ESFT pts 3 tissue arrays More than 200 inclusions for EM WP3: Prognostic relevance of selected promising predictive markers

  12. Evaluation of prognostic value of new genes GALS3BP HINT1 STOML2 CANX FVT1 RPS4Y1 Prognostic value in a very small clinical series: 36 primary untreated biopsies, homogenous for histology, checked for RNA quality • Confirmatory studies: Protein analysis  Tissue Array • Functional studies: in vitro siRNA silencing or forced expression

More Related